-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HIV-1-protease-IN-2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2248124-46-9.gif)
| Category | HIV Integrase |
| CAS | 2248124-46-9 |
| Description | HIV-1 protease-IN-2 is a potent HIV-1 protease inhibitor with an IC50 of 2.53 nM. HIV-1 protease-IN-2 shows antiviral activity against DRV (Darunavir)-sensitive or DRV-resistant HIV-1 variants. |
Product Information
| Synonyms | HIV-1 protease-IN-2|CHEMBL4452255|BDBM50504885|HY-146888|CS-0439010|N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl-(4-methoxyphenyl)sulfonyl-amino]propyl]-2-(2,4-dioxopyrimidin-1-yl)acetamide |
| Molecular Weight | 558.65 |
| Molecular Formula | C27H34N4O7S |
| Canonical SMILES | CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)CN2C=CC(=O)NC2=O)O)S(=O)(=O)C3=CC=C(C=C3)OC |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 967 |
| Exact Mass | 558.21482061 |
| In Vitro | HIV-1 protease-IN-2 (compound 10e) (100 nM) shows a promising inhibition ratio of 68% at 100 nM for wild-type HIV-1. HIV-1 protease-IN-2 (0-1000 nM) shows antiviral activity against DRV (Darunavir)-sensitive or resistant pseudotyped HIV-1 with EC50s of 0.27 µM and 0.59 µM for HIV-1NL4-3 and HIVRDRVS, respectively. |
| Target | IC50: 2.53 nM (HIV-1 protease) |
| XLogP3-AA | 2.1 |
